Litcius/Paper detail

Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis

Deepan Dalal, Tingting Zhang, Theresa I. Shireman

2020Seminars in Arthritis and Rheumatism16 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAdalimumabEtanerceptRheumatoid arthritisAbataceptInfliximabInternal medicineDiseaseRituximabLymphomaRheumatoid Arthritis Research and TherapiesMedication Adherence and ComplianceBiosimilars and Bioanalytical Methods
Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis | Litcius